Respiratory syncytial virus (RSV)-infected cotton rats (Sigmadon hispidus) and owl monkeys (Aotus trivirgatus) showed significant reductions in RSV shedding from their respiratory tracts following parenteral therapy with human intravenous immunoglobulin (IVIG) containing high titers of RSV-neutralizing antibody. Because this therapy was well tolerated and appeared safe, a double-blind, placebo-controlled IVIG immunotherapy pilot study was performed on 35 hospitalized, RSV-infected infants and children. The treatment was well tolerated and resulted in significant reductions in nasal RSV shedding and in improvements in transcutaneous oximetry readings. However, the mean duration of hospitalization was not reduced by IVIG treatment. Followup to date has revealed no harmful effects resulting from immunotherapy of RSV infections. These studies appear to refute the hypothesis that passively acquired antibody may exacerbate RSV bronchiolitis or pneumonia in infants. Studies with larger numbers of seriously ill children will be required to determine if immunoglobulin G immunotherapy of RSV infections in infants is of clinical value.
Respiratory syncytial virus (RSV) is an important respiratory pathogen of infants and young children. The virus produces annual epidemics of bronchiolitis and pneumonia in children throughout the world and causes numerous hospital admissions, substantial morbidity, and some mortality (2, 5, 7, 15, 17, 30, 31) . Efforts to produce an effective vaccine for prevention of these infections have thus far been unsuccessful (16, 19, 35) . Only recently, with the introduction of ribavirin, has treatment other than supportive therapy been available for children with serious RSV infections (1, 6, 11, 12, 29, 32) .
The current studies were prompted by a series of observations: (i) pups of RSV-immune cotton rat mothers were protected from RSV infection, presumably by transplacental antibody (25) ; (ii) injection of serum from RSV-immune cotton rats protected nonimmune cotton rats from RSV infection (26) ; (iii) high-titered RSV-immune human serum and human immunoglobulin prepared for intravenous administration (IVIG) were effective for both prophylaxis and therapy of RSV infections in cotton rats and owl monkeys (13, 24) ; (iv) some lots of human IVIG contained substantial titers of neutralizing antibody to RSV (14) ; and (v) careful pathological studies of the lungs of RSV-infected animals treated with IVIG revealed no evident microscopic pulmonary abnormalities characteristic of the formation of antigenantibody complexes or other untoward pulmonary reactions (13, 24) . The current study was designed to determine if IVIG containing substantial levels of RSV-neutralizing antibody could be safely administered and if it would hasten clinical recovery when infused into RSV-infected, hospitalized children.
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MATERIALS AND METHODS
Institutional review. The protocols for these studies were reviewed and approved by the Institutional Review Committees of Children's Hospital National Medical Center. Authorization was initially given to study 10 (33) . On the day after completion of drug infusion (day 1), the following laboratory and clinical assessments were carried out: oropharyngeal-nasal washes for RSV titration, transcutaneous oximetry, collection of serum for IgG and RSVneutralizing-antibody titers, and detailed assessments of the clinical status of the patient. Thereafter, the oximetry results, RSV titers, and clinical statuses of the patients were monitored daily until the time of discharge. Admission clinical assessments and severity scoring (12, 29) were performed only by either of two experienced investigators (W.R. or H.W.K.) to ensure consistency. Laboratory and clinical assessments performed at discharge were physical examination, oropharyngeal-nasal washes for RSV titration, whole blood collection for T-and B-lymphocyte counts and mitogenesis studies (performed only on the first five children treated with IVIG and the first five treated with albumin), oximetry, complete blood count, serum glutamic oxalacetic transaminase, bilirubin, creatinine, blood urea nitrogen, RSV-neutralizing-antibody titers, and chest X ray.
(v) Data collection after discharge. About 6 weeks after discharge, each child underwent an-outpatient assessment to determine general health status, and blood was obtained for complete blood count, quantitative IgG, RSV-neutralizingantibody titers, and tetanus antibody titers. Seven children had serum obtained after their second diphtheria-pertussistetanus (DPT) immunization injection and 6 weeks after their third DPT immunization.
Laboratory procedures. Blood counts, serum glutamic oxalacetic transaminase, creatinine, blood urea nitrogen, and T-and B-cell counts and mitogenesis were performed by standard laboratory procedures. RSV antigens in cells from nasal swabs were detected by previously published fluorescent-antibody procedures (18) . Quantitative RSV titers in HEp-2 cell cultures were determined by previously published methods (2) . IgG levels-were determined by radial immunodiffusion with commercial kits (Meloy Laboratories, Springfield, Va.). RSV neutralization tests were-performed by a 60% plaque reduction assay (21, 28 evidence that the enhancement of pulmonary pathology in RSV-infected recipients of a Formalin-inactivated RSV vaccine resulted from an action of Formalin on RSV (27) . It was demonstrated (25, 28) that RSV immunity in cotton rats correlated with neutralizing-antibody levels. Further, human serum or purified IgG (24) could be used successfully in immunoprophylaxis or immunotherapy of RSV infections in cotton rats. No type 3 reactions were observed in the lungs of animals naturally immune or passively immunized with cotton rat or human IgG when they were challenged with RSV.
In a large epidemiological study, Parrott and co-workers observed that, though most severe RSV disease occurred in infants less than 6 months of age, there was some sparing from illness of infants less than 2 months of age, a period when passively acquired maternal IgG-RSV antibodies are present in largest amounts (23) . More recently, several workers have demonstrated an apparent protective effect of transplacental antibody in newborns, as measured in serum or cord blood (8, 20, 22, 34) . Bruhn and Yeager (3) found no correlation between cord blood complement fixation RSV antibody and the severity of disease in RSV-infected infants.
Once there was convincing evidence that humoral immunity protected against rather than accentuated RSV disease in infants, immunotherapy of RSV infections was examined in animal models. RSV-infected cotton rats (24) and owl monkeys were treated with human IVIG (13) . In these animals, highly significant reductions in the amounts of RSV recovered from lungs or tracheal lavage specimens were observed. The therapy was also well tolerated. Careful histologic examination of the lungs of RSV-infected, IgGtreated animals revealed no evidence of antibody-induced, enhanced disease. The results from the use of Formalininactivated RSV vaccine in the cotton rat (27) , RSV immunotherapy in the cotton rat (24) , owl monkey studies (13) , and the demonstration of substantial RSV antibody titers in licensed human IVIG preparations (14) suggested that a trial of IgG immunotherapy in RSV-infected infants should be done.
The findings in the current trial confirm that human IgG, which had substantial levels of RSV-neutralizing antibody, was well tolerated and safe when infused into RSV-infected infants and young children. We observed no evidence of disease exacerbation or prolongation, and the high doses of IgG (2 g/kg) did not appear to induce physiologic problems. The short hospital stays suggest that most infants studied were not critically ill. The infusions resulted in significant increases in IgG levels and titers of circulating RSVneutralizing antibody. Significant changes were also observed in the amounts of RSV recovered by titration from nasopharyngeal secretions and in levels of oxygen saturation as determined by transcutaneous oximetric measurements in the IVIG-treated children. Followup of 86% of the children, for as long as 2 years for some (16 of the first 21 patients), has thus far detected no evident long-term sequelae from the treatment. Furthermore, the three IVIG-treated infants who were subsequently immunized with DPT responded as well as placebo-treated children did to the tetanus antigen.
Ribavirin (1-beta-D-ribofuranosyl-1-1,2,4,-triazole-3-carboxamide) is the treatment of choice for children hospitalized with serious RSV infections. Ribavirin variably reduces RSV shedding from the respiratory tract, improves oxygenation, and hastens clinical recovery (1, 6, 11, 12, 29, 32) . The responses measured in our patients, i.e., reduction in RSV shedding and improvement of transcutaneous oximetry, were similar to those observed in the ribavirin studies. As ribavirin and IgG inhibit RSV replication by different mechanisms, studies seem indicated to determine if combination therapy may be more effective than either alone. A recent report (9) of combined immunoglobulin and ribavirin treatment of RSV-infected cotton rats supports this approach.
In summary, the intravenous infusion of IVIG into infants and young children with documented RSV infections was well tolerated. Bronchiolitis or pneumonia was not exacerbated. Significant improvements in oxygenation and reductions in RSV shedding from the respiratory tract suggest that this method of treatment should be further studied with IgG with higher RSV antibody titers in children with more serious RSV disease and perhaps in combination with ribavirin.
